Search the RE article base
Contact Information
Top 48 Hour View List
Useful Web Sites
Category Archives: Policy
Peace measures
In 1917, in the United States, six million people suffered from syphilis. The only drug that offered some relief at the time was an arsenic compound made in Germany called salvarsan. The United States entered the first world war against … Continue reading
A century of reaping enormous profits at the expense of sickness and misfortune, 3
The Mayo doctors, having made their specific arguments with regard to salvarsan in their 1917 letter to Congress, end with a full scale plea, not only to cancel the patent for salvarsan but also for other German drugs, and for … Continue reading
Posted in Bayh-Dole, History, Policy
Tagged Bayh-Dole, megamonopolist, NISTwits, royalties
Leave a comment
A century of reaping enormous profits at the expense of sickness and misfortune, 2
Mayo’s research publication Discovery’s Edge recently ran an article on “The Power of Patents.” In the article, Mayo Clinic wonders about patent royalties from a famous past invention: When Mayo Clinic colleagues Edward Kendall, Ph.D., and Philip Hench, M.D., along with … Continue reading
A century of reaping enormous profits at the expense of sickness and misfortune, 1
In June 1917, the United States had just entered the first world war against Germany, and a German chemical maker through its American subsidiary Farbwerke-Hoechst held U.S. patents on salvarsan, a medicine used to treat syphilis. Along letters written on … Continue reading
Posted in Bayh-Dole, Commons, History, Policy
Tagged Bayh-Dole, drug patent, Mayo, salvarsan
Leave a comment
NIST does not understand the government license in Bayh-Dole
NIST has issued a draft green paper that consolidates all the fake history, pseudo data as fact, misrepresentations of Bayh-Dole, and misconceived proposals all in one convenient place. I can’t hope to catch everything, but let’s take a look at … Continue reading
NIST’s “substantially fueled” premise for unleashing innovation
Here is a claim from the opening of a recent NIST report–1234–on “Unleashing American Innovation,” a “draft green paper”: The U.S. innovation system is substantially fueled by the discoveries and inventions arising from federally funded R&D at the Nation’s universities, … Continue reading
Posted in Innovation, Metrics, Policy
Tagged innovation, NIST, patents, research
Comments Off on NIST’s “substantially fueled” premise for unleashing innovation
Nine Points to Consider (with regard to AUTM’s licensing survey), 8-9
We are considering nine points with regard to AUTM’s annual licensing survey. We have got through seven points–not validated and with estimates, duplicate reporting, conflating technology and invention, activity measures giving the illusion of a process at work, no reporting … Continue reading
Nine Points to Consider (with regard to AUTM’s licensing survey), 1-7
The Association of University Technology Managers, a front group for university licensing professionals, conducts an annual survey of the universities that its members work for. The survey asks for various metrics regarding inventions, patenting, licensing, startups, and revenue. The survey … Continue reading
Nixon’s Need and Encouragement
In a series of articles we have dealt with the monopoly meme. The monopoly meme argues that the true purpose of patents is the corporate right to exclude all others from practicing an invention. Without this right of exclusion, so … Continue reading
15 USC 2218(d)
A federal statute passed in 1974 establishes a federal policy with regard to inventions made with federal support–15 USC 2218(d). Folks wrapped up with Bayh-Dole don’t often mention 15 USC 2218, which establishes the authority of the administrators of federal … Continue reading
Posted in Bayh-Dole, Policy
Tagged 15 USC 2218, Bayh-Dole, FARs, Federal Procurement Regulations, preemption
Comments Off on 15 USC 2218(d)